Sesen Bio Inc. (NASDAQ:SESN) and Forty Seven Inc. (NASDAQ:FTSV) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sesen Bio Inc.	N/A	0.00	33.69M	-0.67	0.00
Forty Seven Inc.	N/A	0.00	65.49M	-2.06	0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Sesen Bio Inc. and Forty Seven Inc.

Profitability

Table 2 provides us Sesen Bio Inc. and Forty Seven Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sesen Bio Inc.	0.00%	-85.7%	-33.6%
Forty Seven Inc.	0.00%	0%	0%

Liquidity

Sesen Bio Inc.’s Current Ratio and Quick Ratio are 9.1 and 9.1 respectively. The Current Ratio and Quick Ratio of its competitor Forty Seven Inc. are 11.9 and 11.9 respectively. Forty Seven Inc. therefore has a better chance of paying off short and long-term obligations compared to Sesen Bio Inc.

Institutional & Insider Ownership

Roughly 45.2% of Sesen Bio Inc. shares are owned by institutional investors while 67.3% of Forty Seven Inc. are owned by institutional investors. 6.56% are Sesen Bio Inc.’s share owned by insiders. On the other hand, insiders owned about 5.1% of Forty Seven Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Sesen Bio Inc.	14.36%	30.32%	-43.45%	-50.26%	2.59%	-33.1%
Forty Seven Inc.	1.35%	17.43%	-6.15%	12.09%	0%	9.73%

For the past year Sesen Bio Inc. had bearish trend while Forty Seven Inc. had bullish trend.

Summary

Forty Seven Inc. beats Sesen Bio Inc. on 4 of the 6 factors.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.